Abstract
Background Use of MRI as a tool to aid in neuroprognostication after cardiac arrest (CA) has been described, yet details of specific indications, timing, and sequences are unknown. We aim to define the current practices in use of brain MRI in prognostication after pediatric cardiac arrest.
METHODS A survey was distributed to pediatric institutions participating in three international studies. Survey questions related to center demographics, clinical practice patterns of MRI after CA, neuroimaging resources, and details regarding MRI decision support.
RESULTS Response rate was 31% (44/143). Thirty-four percent (15/44) of centers have a clinical pathway informing the use of MRI after CA. Fifty percent (22/44) of respondents reported that an MRI is obtained in nearly all CA patients and 32% (14/44) obtain an MRI in those who did not return to baseline neurological status. Sixty-four percent of centers (28/44) obtain an MRI greater than 72 hours after return of spontaneous circulation. Poor neurologic exam was reported as the most common factor (91% [40/44]) determining the timing of the MRI. Conventional sequences (T1, T2, FLAIR, and diffusion weighted imaging/apparent diffusion coefficient) are widely used. Advanced imaging techniques, such as MR spectroscopy, diffusion tensor imaging and resting state functional MRI are less commonly used.
CONCLUSIONS Conventional brain MRI is a common practice for prognostication after CA. Advanced imaging techniques, are used infrequently. The lack of standardized clinical pathways and variability in reported practices support a need for higher-quality evidence regarding the indications, timing, and acquisition protocols of clinical MRI studies.
Competing Interest Statement
Declarations of Interest: Dr. Fink receives funding from National Institute of Neurological Disorders and Stroke (NINDS) R01NS096714; Neurocritical Care Society Incline Grant Dr. Piantino receives support from the National Institute of Health, National Heart, Lung, and Blood Institute; grant K23HL150217 Dr. Press has performed paid expert testimony and provides consulting for Marinus Pharmaceuticals The remainder of the authors have no relevant interests to disclose.
Funding Statement
Juan Piantino: National Heart, Lung, and Blood Institute (NHLBI) K23HL150217 Ericka Fink: National Institute of Neurological Disorders and Stroke (NINDS) R01NS096714
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Pittsburgh Institutional Review Board as Not Human Research (STUDY20010055).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Dual first authors
Funding: Juan Piantino: National Heart, Lung, and Blood Institute (NHLBI) K23HL150217
Ericka Fink: National Institute of Neurological Disorders and Stroke (NINDS) R01NS096714
Declarations of Interest: Dr. Fink receives funding from National Institute of Neurological Disorders and Stroke (NINDS) R01NS096714; Neurocritical Care Society Incline Grant
Dr. Piantino receives support from the National Institute of Health, National Heart, Lung, and Blood Institute; grant K23HL150217
Dr. Press has performed paid expert testimony and provides consulting for Marinus Pharmaceuticals The remainder of the authors have no relevant interests to disclose.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
